Guilford-based Hyperfine Inc., the medical device maker behind a portable bedside MRI system, said it is expected to join the Russell 2000 and Russell 3000 stock indexes in June. The inclusion will become effective after the U.S. market closes on June 26, the company said. The move will give Hyperfine exposure to a broader pool […]
Guilford-based Hyperfine Inc., the medical device maker behind a portable bedside MRI system, said it is expected to join the Russell 2000 and Russell 3000 stock indexes in June.
The inclusion will become effective after the U.S. market closes on June 26, the company said.
The move will give Hyperfine exposure to a broader pool of institutional investors, since the Russell indexes serve as benchmarks for roughly $12.2 trillion in assets, according to FTSE Russell data from June 2025.
Each year, FTSE Russell updates the makeup of its U.S. stock indexes by re-ranking publicly traded companies based largely on market value. The annual reshuffle includes the 4,000 largest U.S. companies, with larger firms placed in the Russell 1000 and smaller companies in the Russell 2000. Membership in the broader Russell 3000 includes companies in both indexes.
“We believe this inclusion reflects the continued progress in executing our commercial strategy, broadening awareness and driving adoption of our portable MRI technology and creating long-term value for shareholders,” said Maria Sainz, Hyperfine’s president and CEO.
Hyperfine’s flagship product is the Swoop system, the first Food and Drug Administration-cleared portable, ultra-low-field MRI device designed to image the brain. The technology allows
bedside scans in hospitals, clinics and other settings where conventional MRI machines aren’t practical.
In March, Hyperfine secured up to
$40 million in debt financing from Farmington-based Horizon Technology Finance Corp., receiving an initial $15 million tranche with another $25 million available through 2027.
Earlier, in October 2025, Hyperfine
raised roughly $17.5 million in a public stock offering priced at $1.25 per share. The company has said the recent financing extends its cash runway into 2028.
The company has yet to earn a profit. Hyperfine reported $13.6 million in revenue for 2025, up 5.2% from the prior year, with a net loss of about $35.6 million. As of mid-February, the company had 102 employees, down from 111 a year earlier.
